Comparative effectiveness of existing medical therapy for atrial fibrillation in hypertrophic cardiomyopathy (AF-HCM)

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Ms Sarah Huang

Stanford University School of Medicine, Palo Alto (United States of America)

6 More presentations in this session

Presentation thumbnail

Beyond absolute epicardial fat: metabolic disproportionality predicts atrial fibrillation recurrence

Doctor F. Martins Nunes (Vila Nova de Gaia, PT)

Presentation thumbnail

Atrial fibrillation in familial amyloid polyneuropathy: prevalence, clinical profile, and anticoagulation challenges

Doctor M. Pereira Santos (Porto, PT)

Presentation thumbnail

Prolonged postoperative atrial fibrillation (>48 Hours) identifies patients at risk of early and late heart failure and reduced survival after cardiac surgery

Assistant Professor M. Klinceva (Skopje, MK)

Presentation thumbnail

Impact of sodium-glucose cotransporter-2 inhibitors on recurrence after atrial fibrillation ablation in patients with indications for SGLT2i therapy

Doctor A. Castro Pinto (Guimaraes, PT)

Presentation thumbnail

Mechanical and electrical atrial remodelling: associations between left atrial strain, premature atrial contraction burden and p-wave indices in a population-based cohort

Mr H. Zilic (Malmo, SE)

Access the full session

Session thumbnail

Atrial fibrillation and myocardial substrate

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Presentation

Interactive discussion and Q&A

Congress Session

EHRA Myths - Device-detected atrial fibrillation

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources